This article is more than 5 years old. Information may no longer be current.
New neuromodulators on the way to US market
Click Here to Manage Email Alerts
WAILEA, Hawaii — Two new botulinum toxins, with different uses and indications that could assist in an ophthalmologist’s arsenal, may be on their way to the American market, according to a speaker here.
“What we really need in this country and beyond are toxins that are a little bit different than everything else on the market,” Steve Yoelin, MD, said at Hawaiian Eye 2018.
The products in development include DaxibotulinumtoxinA (RT002, Revance Therapeutics), a filler that that is believed to last longer, and a serotype E product, EB-001 (Bonti), which is quick acting at its onset but short in duration, making it useful for pain control.
Yoelin’s discussion of neuromodulators also included tips for ophthalmologists who choose to use them.
Brushing up on anatomy can be a boon for those who want to be more successful with injections.
“It’s extremely helpful for everything we do, but also it will make you feel much safer and a much more effective injector — a better doctor,” he said.
Botulinum toxins have multiple indications, including affecting the facial shape and structure as well as eliminating lined skin and improving skin tone and texture, he added.
“I think ophthalmologists are uniquely qualified to do this type of work just because of what we do on a daily basis and especially if you’re in the OR,” he said. “The skills you use under the microscope are very similar.” – by Rebecca L. Forand
Reference: Yoelin S. Neuromodulators. Presented at: Hawaiian Eye 2018; Jan. 13-19, 2018; Wailea, Hawaii.
Disclosure: Yoelin reports he is a consultant for Allergan, Bonti, Galderma and Revance.